

## Job Description – Analytical Scientist

### Responsibilities:

- Develop and validate biomarker, cell-based, and immuno assays for support of preclinical, clinical and product release studies
- Serve as lead scientist on assay development project and assay qualification/validation
- Independently write protocols and reports for qualification and validation
- Manage and perform method development, optimization, qualifications, and validations using internal resources
- Review and author test procedures, qualification protocols and reports
- Manage and oversee analytical activities performed at CROs/CDMOs associated with method development and characterization for drug substance, drug product and reference standards
- Develop new test methods for the characterization of purity and potency of cell-based intermediates and drug product
- Supply development materials to support research/nonclinical studies, analytical development, and CDMO tech transfer activities
- Maintain excellent written documentation of completed experiments (e.g. electronic lab notebook and study reports)

### Qualifications:

- PhD in molecular biology, biochemistry, immunology, biotechnology, or related field at least 3 years of experience of industry experience in assay /analytical development
- Previous experience with cell and gene therapy is a plus
- Knowledge of cGMP manufacturing and process development/validation is a plus
- Attention to detail, critical analysis of data and troubleshooting abilities
- Good writing and communication skills; ability to understand and communicate scientific information
- Highly collaborative working style, and ability to adapt in a fast-paced
- Ability to work with minimal direction to meet objectives and timelines, adapting to changes and priorities in order to fulfill our mission

### About Avenge Bio:

Avenge Bio, Inc. is an oncology-focused biotechnology company developing transformative cell-based immunotherapeutic products for the treatment of intractable solid tumors by incorporating its LOCOcyte™ platform. The LOCOcyte™ platform leverages proprietary engineered cells delivered to the local tumor environment that generate high concentrations of immune effector molecules in proximity to the tumor. This initiates a robust, local and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. Avenge has additional pipeline candidates for the treatment of a wide range of cancers including pancreatic, lung and breast cancers. Avenge Bio was founded in 2019 based upon technology developed in the laboratory of Omid Veisheh, Ph.D. and has an exclusive license from Rice University for this technology. To learn more, visit [www.avengebio.com](http://www.avengebio.com)